Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | TPMT | P51580 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22905946 | 0.87 | CA12 (0.58) | SMPD1HDAC1HDAC8HDAC6CA12 | |
| SCHEMBL20472387 | 0.82 | CA12 (0.58) | SMPD1HDAC1HDAC8HDAC6CA12 | |
| SCHEMBL25564641 | 0.80 | CA12 (0.55) | SMPD1HDAC1HDAC8HDAC6CA12 | |
| SCHEMBL29375753 | 0.79 | SMPD1 (0.75) | SMPD1HDAC1HDAC8HDAC6CA12 | |
| SCHEMBL1029034 | 0.79 | SMPD1 (0.75) | SMPD1HDAC1HDAC8HDAC6CA12 | |
| Hydrochloric Acid SCHEMBL6586504 | 0.78 | SMPD1 (0.73) | SMPD1HDAC1HDAC8HDAC6CA12 | |
| SCHEMBL11271923 | 0.78 | SMPD1 (0.73) | SMPD1HDAC1HDAC8HDAC6CA12 | |
| SCHEMBL30460516 | 0.78 | SMPD1 (0.58) | SMPD1HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL242563 | 0.76 | MRGPRX4 (0.77) | SMPD1HDAC1HDAC8HDAC6CA12 | |
| SCHEMBL27496908 | 0.76 | KMT2A (0.41) | SMPD1HDAC1HDAC8HDAC6NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167082-A1 | PRODRUGS IN THE MODULATION OF INTERLEUKIN | BRISTOL-MYERS SQUIBB COMPANY | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167082-A1 | PRODRUGS IN THE MODULATION OF INTERLEUKIN | TYK2, IL2, IRAK2 | SMPD1 1752/4885HDAC1 1542/4885HDAC8 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.